Request more information about Esbriet® (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF)
You are now registering for information that is intended for healthcare professionals
By registering at this site, you certify that you are a healthcare professional licensed in the United States or its territories and are indicating that you wish to receive information about Esbriet, other Genentech products, and related disease education. Genentech's intent is to only provide information to healthcare professionals licensed in the United States or its territories who would likely be treating patients within the FDA-approved indications for this product.
Your contact information (* indicates a required field)
You have successfully registered to receive additional information about Esbriet® (pirfenidone)
Be sure to add Esbriet@mail.genentech.com to your address book and allowed senders list to ensure you receive the information you requested.
Note that you can unsubscribe from further communications from Genentech at any time.